Should you buy BioCryst Pharmaceuticals (BCRX)?
Updated
BioCryst has delivered four consecutive earnings beats averaging roughly 99% above estimates and trades at 13.3 times forward earnings with a 30% free cash flow margin, creating a setup with roughly 104% upside to analyst consensus; a 15% short interest and 116% implied volatility mean any earnings stumble would be met with outsized selling pressure.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
Despite recording a GAAP loss, the company generates a 30% free cash flow margin and an 11.5% FCF yield, confirming that its underlying economics are cash-generative and self-funding. Quality breakdown | Free cash flow margin remains above 20% over the next four quarters, confirming the business does not need to raise equity to fund operations. | →Stable |
| CounterFree cash flow materially exceeding a net loss can be driven by favorable working-capital timing or deferred charges rather than durable operating efficiency; if those tailwinds normalize, cash generation could compress quickly. | ||
Four consecutive quarters of positive earnings surprises averaging roughly 99% demonstrate that the business has been generating results well above analyst models, suggesting estimates have been persistently conservative. Earnings | The beat streak extends to six or more quarters with average surprises remaining above 25% over the next 12 months. | →Stable |
| CounterA 99% average surprise rate reflects a period when consensus models were dramatically under-calibrated; as analysts reset estimates higher, the structural cushion for outperformance narrows and even modest guidance tightening could flip the streak. | ||
A forward P/E of 13.3 times and a PEG ratio of 0.10 place the stock in attractively valued territory relative to its growth profile, offering a low-cost entry point for the fundamental case. Valuation breakdown | The forward P/E holds below 20 times over the next 12 months as earnings estimates remain intact or rise, sustaining the value argument. | →Stable |
| CounterA PEG of 0.10 likely reflects analyst models built on a narrow earnings ramp from a single product cycle; if revenue growth proves lumpy or decelerates, consensus estimates reset and the apparent cheapness evaporates. | ||
Despite recording a GAAP loss, the company generates a 30% free cash flow margin and an 11.5% FCF yield, confirming that its underlying economics are cash-generative and self-funding.
→Stable- Expectation
- Free cash flow margin remains above 20% over the next four quarters, confirming the business does not need to raise equity to fund operations.
CounterFree cash flow materially exceeding a net loss can be driven by favorable working-capital timing or deferred charges rather than durable operating efficiency; if those tailwinds normalize, cash generation could compress quickly.
Four consecutive quarters of positive earnings surprises averaging roughly 99% demonstrate that the business has been generating results well above analyst models, suggesting estimates have been persistently conservative.
→Stable- Expectation
- The beat streak extends to six or more quarters with average surprises remaining above 25% over the next 12 months.
CounterA 99% average surprise rate reflects a period when consensus models were dramatically under-calibrated; as analysts reset estimates higher, the structural cushion for outperformance narrows and even modest guidance tightening could flip the streak.
A forward P/E of 13.3 times and a PEG ratio of 0.10 place the stock in attractively valued territory relative to its growth profile, offering a low-cost entry point for the fundamental case.
→Stable- Expectation
- The forward P/E holds below 20 times over the next 12 months as earnings estimates remain intact or rise, sustaining the value argument.
CounterA PEG of 0.10 likely reflects analyst models built on a narrow earnings ramp from a single product cycle; if revenue growth proves lumpy or decelerates, consensus estimates reset and the apparent cheapness evaporates.
▸ Show 1 more pillar▾ Show fewer
Short interest at 15% of float combined with implied volatility at 116% signals that a meaningful share of the market is positioned against the stock, creating severe binary downside risk if the earnings trajectory breaks.
→Stable- Expectation
- Short interest declines below 10% of float over 12 months as sustained fundamental progress removes the bearish conviction underpinning the position.
CounterA high short float in a beat-streak stock is a coiled spring: forced covering on continued beats can amplify upside, turning the short concentration from a risk into an accelerant for gains.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Four consecutive quarters of positive earnings surprises averaging roughly 99% demonstrate that the business has been generating results well above analyst models, suggesting estimates have been persistently conservative.
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P2A forward P/E of 13.3 times and a PEG ratio of 0.10 place the stock in attractively valued territory relative to its growth profile, offering a low-cost entry point for the fundamental case.
Trip ifForward P/E expands above 25x from the current 13.3 times as earnings estimates are revised downward.
- P3Despite recording a GAAP loss, the company generates a 30% free cash flow margin and an 11.5% FCF yield, confirming that its underlying economics are cash-generative and self-funding.
Trip ifFree cash flow margin falls below 10% for 2 consecutive quarters from the current 30% level.
- P4Short interest at 15% of float combined with implied volatility at 116% signals that a meaningful share of the market is positioned against the stock, creating severe binary downside risk if the earnings trajectory breaks.
Trip ifShort interest rises above 20% of float from the current 15%.
How the engine reached this verdict
TrendMatrix's engine output for BioCryst Pharmaceuticals, Inc. (BCRX) is HOLD_IF_HOLDING with medium conviction, score 6.2/10 at $10.09. None of the engine's positive-conviction paths (C-quality, D-momentum) cleared their gates — the F-path HOLD reflects balanced signals rather than directional conviction.
BioCryst Pharmaceuticals, Inc. (BCRX) sits at overall score 6.2/10 with no actively-failing gates (strongest-cleared: MOMENTUM:6.6>=5.5). HOLD flips toward BUY_WAIT when a positive-conviction path (C-quality or D-momentum) triggers; toward SELL when any of the currently-passing gates drop below threshold or three+ dimensions fall below 4 simultaneously.
The engine is not issuing fresh-money entry targets at the current verdict. The technical entry zone is around — with a technical stop near $9.52 for existing positions. Asymmetric R:R is 11.57, below the threshold (≥2.0) at which the engine would actively flag fresh capital. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
On the bull side: Strong earnings beat streak (4/4); Attractive valuation; Strong growth profile. On the bear side: Near 52-week high (0.8% away); Overbought (RSI 83).
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates BCRX — 10-dimension breakdown →
Bull case
- ▸Strong earnings beat streak (4/4)
- ▸Attractive valuation
- ▸Strong growth profile
Bear case
- ▸Near 52-week high (0.8% away)
- ▸Overbought (RSI 83)